Effective apatinib treatment of pleomorphic liposarcoma: A case report

Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2017-08, Vol.96 (33), p.e7771-e7771
Main Authors: Yan, Peng, Sun, Mei-Li, Sun, Yu-Ping, Liu, Chuan-Yong
Format: Article
Language:English
Subjects:
Aged, 80 and over
Clinical Case Report
Disease-Free Survival
Female
Humans
Liposarcoma - drug therapy
Pyridines - administration & dosage
Pyridines - adverse effects
Pyridines - therapeutic use
Quality of Life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4055-da6fd890717e1079c0bee387ddc34b29c84d248ee163b1fbe599b090d6dc81103
cites cdi_FETCH-LOGICAL-c4055-da6fd890717e1079c0bee387ddc34b29c84d248ee163b1fbe599b090d6dc81103
container_end_page e7771
container_issue 33
container_start_page e7771
container_title Medicine (Baltimore)
container_volume 96
creator Yan, Peng
Sun, Mei-Li
Sun, Yu-Ping
Liu, Chuan-Yong
description Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy. The patient was diagnosed as having PLS by biopsy. After a failed chemotherapy, apatinib started to be taken orally 425 mg per day. This patient achieved 3-month progression-free survival (PFS) and a higher quality of life. Meanwhile, this patient suffered grade 2 hypertension and grade 3 hand-foot syndrome (HFS). In this case, apatinib presented good efficacy and safety to treat PLS. Randomized clinical studies are required to confirm the efficacy and safety of apatinib in the treatment of PLS.
doi_str_mv 10.1097/MD.0000000000007771
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5571695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28816958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4055-da6fd890717e1079c0bee387ddc34b29c84d248ee163b1fbe599b090d6dc81103</originalsourceid><addsrcrecordid>eNpdkc9OwzAMxiMEYmPwBEioL9DhtEmTcECa9geQNnGBc5SmLiu0S5V2m3h7OgbTwBcf7O9n-zMh1xSGFJS4XUyGcBRCCHpC-pTHSchVwk5JHyDioVCC9chF07wD0FhE7Jz0Iilporjsk9k0z9G2xQYDU5u2WBVp0Ho0bYWrNnB5UJfoKufrZWGDsqhdY7x1lbkLRoE1DQYea-fbS3KWm7LBq588IK-z6cv4MZw_PzyNR_PQMuA8zEySZ1KBoAIpCGUhRYylyDIbszRSVrIsYhKRJnFK8xS5UikoyJLMSkohHpD7PbdepxVmtlvSm1LXvqiM_9TOFPpvZVUs9ZvbaM7F7uIOEO8B1rum8ZgftBT0zla9mOj_tnaqm-OxB82vj10D2zdsXdmibz7K9Ra9XqIp2-U3jwsVhRFQAZJKCGH3m_gLbkKEGw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effective apatinib treatment of pleomorphic liposarcoma: A case report</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Yan, Peng ; Sun, Mei-Li ; Sun, Yu-Ping ; Liu, Chuan-Yong</creator><creatorcontrib>Yan, Peng ; Sun, Mei-Li ; Sun, Yu-Ping ; Liu, Chuan-Yong</creatorcontrib><description>Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy. The patient was diagnosed as having PLS by biopsy. After a failed chemotherapy, apatinib started to be taken orally 425 mg per day. This patient achieved 3-month progression-free survival (PFS) and a higher quality of life. Meanwhile, this patient suffered grade 2 hypertension and grade 3 hand-foot syndrome (HFS). In this case, apatinib presented good efficacy and safety to treat PLS. Randomized clinical studies are required to confirm the efficacy and safety of apatinib in the treatment of PLS.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000007771</identifier><identifier>PMID: 28816958</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Aged, 80 and over ; Clinical Case Report ; Disease-Free Survival ; Female ; Humans ; Liposarcoma - drug therapy ; Pyridines - administration &amp; dosage ; Pyridines - adverse effects ; Pyridines - therapeutic use ; Quality of Life</subject><ispartof>Medicine (Baltimore), 2017-08, Vol.96 (33), p.e7771-e7771</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4055-da6fd890717e1079c0bee387ddc34b29c84d248ee163b1fbe599b090d6dc81103</citedby><cites>FETCH-LOGICAL-c4055-da6fd890717e1079c0bee387ddc34b29c84d248ee163b1fbe599b090d6dc81103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571695/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571695/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28816958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Peng</creatorcontrib><creatorcontrib>Sun, Mei-Li</creatorcontrib><creatorcontrib>Sun, Yu-Ping</creatorcontrib><creatorcontrib>Liu, Chuan-Yong</creatorcontrib><title>Effective apatinib treatment of pleomorphic liposarcoma: A case report</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy. The patient was diagnosed as having PLS by biopsy. After a failed chemotherapy, apatinib started to be taken orally 425 mg per day. This patient achieved 3-month progression-free survival (PFS) and a higher quality of life. Meanwhile, this patient suffered grade 2 hypertension and grade 3 hand-foot syndrome (HFS). In this case, apatinib presented good efficacy and safety to treat PLS. Randomized clinical studies are required to confirm the efficacy and safety of apatinib in the treatment of PLS.</description><subject>Aged, 80 and over</subject><subject>Clinical Case Report</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Liposarcoma - drug therapy</subject><subject>Pyridines - administration &amp; dosage</subject><subject>Pyridines - adverse effects</subject><subject>Pyridines - therapeutic use</subject><subject>Quality of Life</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpdkc9OwzAMxiMEYmPwBEioL9DhtEmTcECa9geQNnGBc5SmLiu0S5V2m3h7OgbTwBcf7O9n-zMh1xSGFJS4XUyGcBRCCHpC-pTHSchVwk5JHyDioVCC9chF07wD0FhE7Jz0Iilporjsk9k0z9G2xQYDU5u2WBVp0Ho0bYWrNnB5UJfoKufrZWGDsqhdY7x1lbkLRoE1DQYea-fbS3KWm7LBq588IK-z6cv4MZw_PzyNR_PQMuA8zEySZ1KBoAIpCGUhRYylyDIbszRSVrIsYhKRJnFK8xS5UikoyJLMSkohHpD7PbdepxVmtlvSm1LXvqiM_9TOFPpvZVUs9ZvbaM7F7uIOEO8B1rum8ZgftBT0zla9mOj_tnaqm-OxB82vj10D2zdsXdmibz7K9Ra9XqIp2-U3jwsVhRFQAZJKCGH3m_gLbkKEGw</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Yan, Peng</creator><creator>Sun, Mei-Li</creator><creator>Sun, Yu-Ping</creator><creator>Liu, Chuan-Yong</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20170801</creationdate><title>Effective apatinib treatment of pleomorphic liposarcoma: A case report</title><author>Yan, Peng ; Sun, Mei-Li ; Sun, Yu-Ping ; Liu, Chuan-Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4055-da6fd890717e1079c0bee387ddc34b29c84d248ee163b1fbe599b090d6dc81103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged, 80 and over</topic><topic>Clinical Case Report</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Liposarcoma - drug therapy</topic><topic>Pyridines - administration &amp; dosage</topic><topic>Pyridines - adverse effects</topic><topic>Pyridines - therapeutic use</topic><topic>Quality of Life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Peng</creatorcontrib><creatorcontrib>Sun, Mei-Li</creatorcontrib><creatorcontrib>Sun, Yu-Ping</creatorcontrib><creatorcontrib>Liu, Chuan-Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Peng</au><au>Sun, Mei-Li</au><au>Sun, Yu-Ping</au><au>Liu, Chuan-Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective apatinib treatment of pleomorphic liposarcoma: A case report</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>96</volume><issue>33</issue><spage>e7771</spage><epage>e7771</epage><pages>e7771-e7771</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Pleomorphic liposarcoma (PLS) is a rare and aggressive malignant tumor, and both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. We presented an 81-year-old Chinese woman with advanced PLS who received apatinib after failure chemotherapy. The patient was diagnosed as having PLS by biopsy. After a failed chemotherapy, apatinib started to be taken orally 425 mg per day. This patient achieved 3-month progression-free survival (PFS) and a higher quality of life. Meanwhile, this patient suffered grade 2 hypertension and grade 3 hand-foot syndrome (HFS). In this case, apatinib presented good efficacy and safety to treat PLS. Randomized clinical studies are required to confirm the efficacy and safety of apatinib in the treatment of PLS.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>28816958</pmid><doi>10.1097/MD.0000000000007771</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2017-08, Vol.96 (33), p.e7771-e7771
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5571695
source HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals; PubMed Central
subjects Aged, 80 and over
Clinical Case Report
Disease-Free Survival
Female
Humans
Liposarcoma - drug therapy
Pyridines - administration & dosage
Pyridines - adverse effects
Pyridines - therapeutic use
Quality of Life
title Effective apatinib treatment of pleomorphic liposarcoma: A case report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A59%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20apatinib%20treatment%20of%20pleomorphic%20liposarcoma:%20A%20case%20report&rft.jtitle=Medicine%20(Baltimore)&rft.au=Yan,%20Peng&rft.date=2017-08-01&rft.volume=96&rft.issue=33&rft.spage=e7771&rft.epage=e7771&rft.pages=e7771-e7771&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000007771&rft_dat=%3Cpubmed_cross%3E28816958%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4055-da6fd890717e1079c0bee387ddc34b29c84d248ee163b1fbe599b090d6dc81103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28816958&rfr_iscdi=true